Pharma To Market is a leading regulatory affairs consulting company operating in the Asia-Pacific region. We assist life science companies to register their products and access the diverse and rapidly growing markets throughout Australia, New Zealand and Asia – Singapore, Malaysia, Indonesia, Thailand, The Philippines, Vietnam, Taiwan, Hong Kong, South Korea.
Founded by ex-TGA evaluators and industry specialists, Pharma To Market has a unique understanding of the regulatory landscape in Asia Pacific.
Pharma To Market’s client relationships are built on trust, transparency and reliability, which we achieve through our commitment to quality and excellence. We go the extra mile to achieve results and fit in with your time frame and budget.
Let us be part of your success story!
To become an industry leader through our commitment to customer service, quality, and current and extensive knowledge in our fields of expertise. Our culture of professionalism, honesty, openness and respect will enable us to be a reliable and trusted partner for our clients in the pharmaceutical industry, delivering comprehensive regulatory consulting and outsourcing solutions.
Nick's career in the pharmaceutical industry began in 1997 and since then his roles have spanned international regulatory affairs and strategy, GxP activities, e-Submissions...
Johanna has worked in the biotechnology and pharmaceutical industry since 1999 and has specialised in global regulatory affairs for the last 12 years. Following studies...
Relationships with our clients are built on trust, transparency and reliability.
If we think of a better way of doing things - we'll let our clients know and if we don't know how to do something, we'll find someone who can.
We know that's what our clients deserve and expect. We go the extra mile to achieve results and fit in with our client's time frame and budget.
We keep up-to-date on changes in legislation, guidance and technology; our clients get the best advice in the most expedient manner.
I was looking for someone who could convert my non-electronic Active Substance Master File to eCTD format and submit it to the relevant regulatory authorities in only ten days. After my initial phone conversation with Nick, I was confident that they were capable of doing the work, the only question is my mind was the extremely tight deadline. However, Nick committed to meeting the target and the eCTD formatted ASMF was submitted on time and accepted by the authority. Their fast response to my needs effectively saved our client’s marketing authorization application from being pipped at the post by a competitor.
Subsequently, Pharma To Market have supported the submission through all stages of approval by the authority, giving sound advice when needed and always meeting tight deadlines. The marketing authorization has now been granted.
Pharma To Market have continued providing solid service for the other projects we have since engaged them on and we look forward to continuing our positive association.
New Zealand Pharmaceuticals Ltd, New Zealand
Pharma To Market were extremely efficient in providing the NeeS version of a Module 1 related to a Product information update when IT support was not available from the corporate HQ of a local client. Pharma To Market responded to meet a very tight deadline and were very professional to work with.
O'Shea and Associates Pty Ltd, Australia
The (Authoring eCTD Compliant Documents) workshop was an excellent overview of the documentation requirements for NeeS/eCTD submissions. The ‘hands on’ part of the training highlighted many features within Microsoft Word and Adobe Acrobat which will assist us in producing compliant documentation efficiently in preparation for future eCTD submissions in Australia.
Dr Danielle McLennan
Generic Partners Pty Ltd, Australia
As a mid-sized biopharmaceutical company, we can maximize the value we create for patients by working with partners who effectively extend our reach. Such is the case working with Pharma To Market who has delivered a product registration in Singapore each year since we started our partnership. Pharma to Market works independently with consistency – allowing my in-house team to focus on essential internal collaboration and strategic decision-making. This professionalism builds trust, so when we needed to have Pharma to Market manage product registration in a third country that we did not yet have a significant presence ourselves, it gave us complete peace of mind.
Boon Heon Tan
UCB, Asia Pacific Rim & India
I have had the pleasure of working with Pharma To Market for the last 18 months preparing a particularly challenging regulatory submission for a large multinational pharmaceutical company. Johanna and Nick demonstrated excellent Australian regulatory expertise, providing strong direction and displaying outstanding organizational skills which resulted in the production of a high quality submission within a tight deadline. They have always remained focused and professional and were willing to go the extra mile to complete the task at hand. I would not hesitate to recommend Pharma To Market for their regulatory affairs services and hope that I have the opportunity to work with them in the future.
Francis Upchurch BSc MB ChB DRCOG FFPM
PharmDoc Limited, United Kingdom
The one day (Authoring eCTD Compliant Documents) workshop was run very professionally. All the information provided was relevant and current. There was a very good balance of theory and practical exercises. The take home resources, including the educational workshop guide and the preformatted template continue to be of great help in the day-to-day work of writing and formatting the Modules.
From a personal perspective, I have greatly appreciated the continued assistance from the Pharma To Market team in authoring publishable Modules.
Phebra Pty Ltd, Australia
We chose to work with Pharma To Market to register our products and the experience was excellent. Pharma To Market provided an insightful overview of the registration requirements to aid our understanding of the process. They also took initiatives to identify potential areas of concern. The result was less time spent on the registrations and that allowed us to promptly and efficiently place our brands on the local market.
A|F|T Pharmaceuticals Limited, New Zealand